Dr. William (Bill) Barry has devoted his career to clinical research and efforts to efficiently and rigorously test novel therapeutics and innovative strategies to improve health outcomes in a variety of disease settings.

Earning his Ph.D. in Biostatistics from the University of North Carolina in 2006, Dr. Barry has more than 12 years of experience in Phase 1-3 clinical trials and translational research efforts to discover and validate genomic and proteomic signatures of diseases and molecular measures in response to interventions.

In 2010 while at the Institute for Genome Science and Policy at Duke University, Dr. Barry participated in a large federally-funded collaborative project in order to validate genomic signatures of the host response to the H1N1 virus and to evaluate the platform as a novel approach to diagnosis and detection of infection. At the Duke Cancer Institute and later at the Dana-Farber Cancer Institute, Dr. Barry supported multiple early-phase investigations into whether vaccines can be a novel and promising approach to targeted therapies as well as the enhancement of immune responses in breast cancer.

Rho’s cross-disciplinary and team-based approach to clinical research has been a strong motivator for Dr. Barry in a wide array of activities. Most recently, Dr. Barry participated in the design and conduct of trials for medical and infectious disease countermeasures under the Biomedical and Advanced Research Development Authority (BARDA).

Dr. Barry earned his Ph.D. in Biostatistics from the University of North Carolina in 2006.

This is what drives Dr. Barry:

Throughout his medical career, the opportunity to have a direct impact on health science and to collectively strive for evidence-based practices to medicine and public health has been the inspiration for his work.